Senesco Technologies reported results of cohort 2 in its Phase 1b/2a clinical study of SNS01-T. In cohort 2, the requisite number of 3 patients was evaluable for the primary safety endpoint from the total of 4 enrolled. Two multiple myeloma patients and one diffuse large B-cell lymphoma patient completed the required number of doses to be evaluable. As with the previous dose level, there were no drug-related serious adverse events or dose-limiting toxicities in either the evaluable patients or in the one patient who received only 5 infusions before being withdrawn. Over cohorts 1 and 2 at the two lowest dose levels, stabilization of serum monoclonal protein levels has been observed in three of the five evaluable multiple myeloma patients, and, in three of nine patients overall. “I am very encouraged by the absence of drug-related safety issues at the lower doses with this exciting new targeted approach to treating B-cell cancers,” stated Alice S. Bexon, M.D., Vice President of Clinical Development.